Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exelixis ( (EXEL) ) has issued an announcement.
On August 29, 2025, Exelixis, Inc. announced a significant leadership change as Dana T. Aftab, Ph.D., was appointed as Executive Vice President, Research and Development, succeeding Amy C. Peterson, M.D., who concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer. This transition may impact the company’s strategic direction in research and development, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (EXEL) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Exelixis stock, see the EXEL Stock Forecast page.
Spark’s Take on EXEL Stock
According to Spark, TipRanks’ AI Analyst, EXEL is a Outperform.
Exelixis’s strong financial performance and positive earnings call sentiment are the most significant factors driving its stock score. Technical analysis presents mixed signals, and valuation is moderate. The absence of a dividend yield and potential liquidity risks slightly temper the overall positive outlook.
To see Spark’s full report on EXEL stock, click here.
More about Exelixis
Exelixis, Inc. operates in the biotechnology industry, focusing on the discovery, development, and commercialization of new medicines to treat cancer. The company is known for its innovative approach in oncology, aiming to improve patient outcomes through targeted therapies.
Average Trading Volume: 3,274,728
Technical Sentiment Signal: Buy
Current Market Cap: $10.2B
Find detailed analytics on EXEL stock on TipRanks’ Stock Analysis page.